Compare Anheuser-Busch Inbev SA (BUD) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs DENTSPLY SIRONA Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.63 (market cap $153.45B), while DENTSPLY SIRONA Inc trades at $13.4 (market cap $2.55B). The key difference: Anheuser-Busch Inbev SA is far larger — about 60.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| BUD | XRAY | |
|---|---|---|
Market Cap | $153.45B | $2.55B |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $16.85 |
52-Week Low | $57.10 | $9.64 |
Enterprise Value | $214.64B | $4.69B |
Dividend Yield | 1.7% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
Dentsply Sirona (XRAY) trades at $12.78, up 4.24% today, with technical indicators showing bullish momentum despite recent earnings misses. The company faces fundamental challenges with negative net income margins (-17.06%) and declining revenue trends, though it maintains a solid gross margin of 48.93%. Recent developments include new CFO appointment and expanded distribution partnerships, while analyst consensus remains mixed with a $13.33 price target.
The stock presents a turnaround opportunity with improving cash flow trends and strategic initiatives, but faces significant execution risks amid persistent profitability challenges. Near-term catalysts include Q2 2026 earnings and continued progress on the Return-to-Growth plan, though high debt levels and competitive pressures warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
